中木國際(01822.HK)2024年擁有人應占溢利淨額6380萬港元
格隆匯3月18日丨中木國際(01822.HK)公吿,截至2024年12月31日止年度,集團錄得營業額約3.564億港元(2023年(經重列):約3.12億港元)。集團的公司擁有人應占溢利淨額約為6380萬港元(2023年:約12億港元)。董事會不建議就截至2024年12月31日止年度派付任何末期股息(2023年:零港元)。
集團將繼續探尋與行業供應鏈中游至下游的市場參與者(如房地產開發商、高端家俬品牌零售商、物流管理服務提供商以及管理專業人才)進行戰略合作的潛在機遇,以進一步擴大集團的木材相關業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.